BioCryst Announces Approval Of ORLADEYO By Public Health Institute Of Chile
Portfolio Pulse from Benzinga Newsdesk
BioCryst Pharmaceuticals announced that the Public Health Institute of Chile has approved its oral drug ORLADEYO for the prevention of hereditary angioedema attacks. This approval expands the drug's market reach.
May 22, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioCryst Pharmaceuticals' ORLADEYO has been approved by the Public Health Institute of Chile, potentially increasing the company's revenue.
The approval of ORLADEYO by the Public Health Institute of Chile directly impacts BioCryst Pharmaceuticals (BCRX) as it expands the market reach of the drug. This could lead to increased sales and revenue for the company, positively affecting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100